Please ensure Javascript is enabled for purposes of website accessibility
Cory Renauer

Cory Renauer

tmfang4apples

Cory is a long-term minded analyst focused on the Healthcare Sector. He genuinely enjoys cutting through the complexity to help everyday investors make better decisions.

Recent articles

Investor-watching-stock-tank

Here's Why Sigilon Therapeutics Stock Is Tanking Today

A clinical hold for the company's lead candidate wasn't what investors wanted to hear this morning.


happy-investors-checking-holdings

Here's Why Biohaven Pharmaceutical Is Soaring Today

Preliminary sales figures for the company's new migraine drug were much better than expected.


biotech-laboratory-interaction-getty

Is Eli Lilly a Better Alzheimer's Stock Than Biogen?

An unusually lenient FDA is a knife that cuts both ways for Biogen.


investor-looking-at-sinking-stock-chart

Here's Why Provention Bio Stock Is Diving Today

The company's latest letter from the FDA wasn't what investors had hoped for.


life-science-professionals

Here's What's Pushing Cerevel Therapeutics Stock Lower Today

Investors aren't thrilled about how this biotech intends to pay operating expenses that are about to balloon.

row-of-scientists-getty

Here's What Drove These Stocks Higher This Week

The most exciting clinical trial data in the medical community has huge implications for Intellia, and its peers.


3-frowning-people-looking-at-a-laptop

Here's Why Arrowhead Pharmaceuticals Stock Is Getting Hammered Today

A paused clinical trial with an important asset wasn't what investors wanted to hear today.


doctors-looking-at-tablet

Here's Why Citius Pharmaceuticals Stock Is Losing Ground Today

Another interim analysis has come and gone with an unsatisfying result.


scientists-at-work-laboratory

5 Reasons Alnylam's Still a Top Biotech Stock to Buy Now

Despite a threat from Intellia on the horizon, Alnylam's still in a position to deliver big gains for patient investors.


scientist-presenting-to-investors-getty

Can Intellia Therapeutics Turn Exciting Trial Results into Profits?

New proof-of-concept results are a big deal for the medical community, but what about for your portfolio?

Excited-investor-getty

Here's Why Cerevel Therapeutics Stock Is Shooting Through the Roof Today

Positive topline results from the company's schizophrenia candidate were better than expected.


investor-watching-stock-chart-rising-getty

Here's Why Exelixis Stock Is Dropping Today

The company reported successful clinical trial results, but investors were still disappointed.


smart-doctor-contemplating-your-question-getty

Can Atossa Therapeutics Stock Keep Climbing?

Investors want to know if this clinical-stage cancer drug developer can keep putting up big gains.


frustrated-investor-computer-getty

Here's Why BioXcel Therapeutics Stock Got Hammered This Week

Investors weren't happy about a secondary share offering.


scientist-biotech-comparing-test-tubes-getty

Why Arcus Biosciences' Big Reveal Wasn't Very Exciting

No news from Arcus Biosciences is bad news for the company and other industry heavyweights.

life-science-pro-making-selection-getty

Here's Why Arcus Biosciences Stock Is Rising Today

Investors expecting Gilead Sciences to license Arcus Biosciences' lead asset could be in for an unpleasant surprise.


investor-at-computer-getty

Here's Why Patterson Companies Stock Is Sliding Today

Management's uninspiring outlook for fiscal 2022 was not what investors wanted to hear.


smart-investor-looking-at-spreadsheets-getty

Is It Too Late to Buy Citius Pharmaceuticals Stock?

See if this biotech has what takes to climb even higher.


three-scientists-laboratory-getty

3 Biotech Stocks With Big Catalysts in June

Important events on the horizon could push these biotech stocks higher or press them further into the dirt.


investor-upset-about-recent-loss

Here's Why Sage Therapeutics Tanked This Week

The neuroscience-focused biotech company didn't give investors the result they wanted.